Release date: 2024-08-13 10:38:07 Article From: Lucius Laos Recommended: 171
Pemigatinib is mainly used to treat specific diseases such as advanced or metastatic cholangiocarcinoma caused by FGFR2 fusion or rearrangement.
Pemilitinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangements detected by FDA-approved assays.
Specifically, it is used to treat patients with cholangiocarcinoma that has metastasized (spread to other parts of the body) or is locally advanced and cannot be treated by surgery, especially those with FGFR2 gene fusions or other changes in the structure of the FGFR2 gene.
In some countries and regions, governments regulate and price drug prices. This pricing policy has a direct impact on the market price of the drug.
Different regions have different levels of economic development, and people's ability to pay is also different. This results in different market prices for the drug in different regions. For imported drugs, import tariffs and exchange rate fluctuations can also affect their prices. Tariff increases and decreases and exchange rate fluctuations will change the cost of importing drugs, which in turn will affect the selling price.
The original drug has patent protection and technical advantages, and the price is usually higher. Generic drugs, on the other hand, are marketed after the patent expires and are relatively inexpensive. There is a significant difference in the price of the original drug and the generic drug of Pemigatinib. The sales channel of a drug can also affect its price. Different sales channels may have different pricing strategies and profit margins.
The production process of the original drug is complex and delicate, and the quality of the excipients used is relatively high. The selection of these production processes and excipients is critical to ensuring the quality and stability of drug products. Although generic drugs are similar in composition to the original drug, their production process and choice of excipients may differ. These differences may lead to differences between the generic drug and the original drug in terms of purity, stability, etc.
The original drug needs to complete the complete new drug application process and implement strict international standards. These standards include a thorough and rigorous review and evaluation of all aspects of a pharmaceutical product. Generic drugs only need to go through the simple new drug application process and the implementation of relatively relaxed standards.
The R&D cost of the original drug is high, the cycle is long the risk is high, and the price is usually high. With the inclusion of some original drugs in the medical insurance catalogue and the implementation of the price negotiation mechanism, their prices have gradually become more affordable. Generic drugs are usually priced lower due to their lower R&D costs and short lead times. This makes generic drugs have a greater advantage in price and are more easily accepted by patients.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: